VoxNeuro Announces Collaboration with the Canadian Armed Forces and Launch of Clinical Study Measuring Impact of Training-Related Sub-Concussive Exposure

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

VoxNeuro Inc., a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, recently announced a new partnership with the Canadian Armed Forces (CAF). VoxNeuro and CAF have partnered to study the cognitive effects following intense military training regimens designed to reflect a combat environment and blast exposure. Despite the high prevalence of cognitive issues in veterans and active military personnel, there is relatively little understanding regarding these cognitive effects and reliable monitoring.

The study will assess the effects of repetitive, sub-concussive exposure (RSCE) on cognitive functioning and brain electrophysiology with CAF personnel undergoing cognitive testing in tandem with EEG recordings before and after military training. The study seeks to understand the relationship between RSCE and behavioural symptoms, vestibular dysfunction, neurophysiology, and cognition to aid in early detection, prevention, treatment, and prognosis.

VoxNeuro is an OBIO® member.

Arsheen Kaur
Previous

Winterlight Labs announces data demonstrating the sensitivity of speech-based digital measures in detecting longitudinal change in Alzheimer’s disease in collaboration with Genentech
Next

Immugenia Obtains Pre-Seed Funding from adMare BioInnovations, ACET Capital, and Sherbrooke Innopole to Develop a Cancer Treatment Which Would Prevent Relapses